Arrhythmia Update 2025
Arrhythmia Update 2025 - Save the Date!
What is iMedicus?
iMedicus is Canada’s most innovative livestream CME channel for specialists and family physicians!
Watch Now!
Hyperkalemia management in Heart Failure - Watch Now!
The New HFrontier: Watch Now!
The New HFrontier: Worsening Heart Failure
upcoming
featured
![](/themes/custom/arnett/css/images/icon-podcast-listing.png)
Diabetes Update 2022 Podcast Series
Let’s Be Friends: A Collaborative Conversation between Endocrinology and Cardiology
![](/themes/custom/arnett/css/images/icon-video-listing.png)
A Nephro and Cardio Convo: Common Clinical Questions around Anticoagulation in C
A Nephro and Cardio Convo: Common Clinical Questions around Anticoagulation in CKD
![](/themes/custom/arnett/css/images/icon-video-listing.png)
AIM-LO: PCSK9 inhibition (mAbs and siRNA) - Efficacy & Safety Data
AIM-LO: PCSK9 inhibition (mAbs and siRNA) - Efficacy & Safety Data
![](/themes/custom/arnett/css/images/icon-video-listing.png)
AIM-LO: PCSK9 inhibition (mAbs and siRNA) - Mechanisms of Action
AIM-LO: PCSK9 inhibition (mAbs and siRNA) - Mechanisms of Action
![](/themes/custom/arnett/css/images/icon-video-listing.png)
AIM-LO: Key Tips to Maximize Therapeutic Access for Your Patients
AIM-LO: Key Tips to Maximize Therapeutic Access for Your Patients
![](/themes/custom/arnett/css/images/icon-video-listing.png)
AIM-LO: Engaging With Your Patients about Selection of Injectable Therapies for
Engaging With Your Patients about Selection of Injectable Therapies for LDL-C Reduction
on demand
![](/themes/custom/arnett/css/images/icon-video-listing.png)
A Nephro and Cardio Convo: Common Clinical Questions around Anticoagulation in C
A Nephro and Cardio Convo: Common Clinical Questions around Anticoagulation in CKD
![](/themes/custom/arnett/css/images/icon-video-listing.png)
AIM-LO: PCSK9 inhibition (mAbs and siRNA) - Dosing FAQs
AIM-LO: PCSK9 inhibition (mAbs and siRNA) - Dosing FAQs
![](/themes/custom/arnett/css/images/icon-video-listing.png)
AIM-LO: PCSK9 inhibition (mAbs and siRNA) - Efficacy & Safety Data
AIM-LO: PCSK9 inhibition (mAbs and siRNA) - Efficacy & Safety Data
![](/themes/custom/arnett/css/images/icon-video-listing.png)
AIM-LO: PCSK9 inhibition (mAbs and siRNA) - Mechanisms of Action
AIM-LO: PCSK9 inhibition (mAbs and siRNA) - Mechanisms of Action
![](/themes/custom/arnett/css/images/icon-video-listing.png)
AIM-LO: Key Tips to Maximize Therapeutic Access for Your Patients
AIM-LO: Key Tips to Maximize Therapeutic Access for Your Patients
![](/themes/custom/arnett/css/images/icon-video-listing.png)
AIM-LO: Engaging With Your Patients about Selection of Injectable Therapies for
Engaging With Your Patients about Selection of Injectable Therapies for LDL-C Reduction
![](/themes/custom/arnett/css/images/icon-video-listing.png)
AIM-LO: Overview of 2021 CCS Dyslipidemia Guidelines: Focus Secondary Prevention
AIM-LO: Overview of 2021 CCS Dyslipidemia Guidelines: Focus on Secondary Prevention
listen now
![](/themes/custom/arnett/css/images/icon-podcast-listing.png)
Diabetes Update 2022 Podcast Series
Let’s Be Friends: A Collaborative Conversation between Endocrinology and Cardiology
![](/themes/custom/arnett/css/images/icon-podcast-listing.png)
Diabetes Update 2022 Podcast Series
Incorporating Novel Cardiovascular (Cv) Risk Reduction Strategies for Diabetes Patients: W